5:39 PM
 | 
Apr 30, 2013
 |  BC Extra  |  Company News

GSK submits NDA for umeclidinium bromide monotherapy

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) submitted an NDA to FDA for umeclidinium bromide as monotherapy for the long-term, once-daily maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive...

Read the full 132 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >